Ozanimod- CAS 1306760-87-1

CAS No.: 1306760-87-1

Inquire Ozanimod (cas: 1306760-87-1 ) online by filling out the inquiry form, we will get back to you within 24 hours!

Ozanimod,1306760-87-1
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I001173
Synonyms:

Ozanimod; RPC1063;(S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile

Molecular Formula:

C₂₃H₂₄N₄O₃

Molecular Weight:404.46
Description: Ozanimod(cas# 1306760-87-1), also known as RPC1063, is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). Ozanimod represents a potential franchise in immunology. Ozanimod is the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis.
Price:Get quote

We would like to match the lowest price on market if possible.


Ozanimod(cas# 1306760-87-1), also known as RPC1063, is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

Ozanimod represents a potential franchise in immunology. Ozanimod is the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis. In a Phase 2 trial in patients with RMS, Ozanimod achieved the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of Ozanimod is consistent with the results of prior trials and continues to demonstrate differentiation against other oral agents for treatment of RMS. Ozanimod is also being studied in inflammatory bowel disease (IBD). The TOUCHSTONE Phase 2 trial of Ozanimod in UC met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1.0 mg dose of Ozanimod in the 8-week induction period. The overall safety and tolerability profile of Ozanimod is consistent with the results of the recent Phase 2 trial in RMS, and continues to support the potential for orally administered Ozanimod to significantly improve the treatment paradigm for UC patients.

Ozanimod is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

Chem Calculators

© 2017-2022 MuseChem - A division of ArrakisTek Inc. All Rights Reserved.